Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

2025-04-01 20:50:59 ET

Traws Pharma, Inc. (TRAW)

Virtual Investor Event

March 31, 2025 10:00 AM ET

Company Participants

Werner Cautreels – Chief Executive Officer

Robert Redfield – Chief Medical Officer

David Pauza – Chief Science Officer-Virology

Iain Dukes – Executive Chairman

Bruce Mackle – LifeSci Advisors

Conference Call Participants

Presentation

Operator

Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode. A question-and-answer session will follow the discussion. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Traws’ website following the conclusion of the event.

Before we begin, on this slide, you’ll see Traws’ standard disclaimer language. Statements in this presentation and on this call may be forward-looking, including our plans, objectives and expectations for our antiviral pipeline programs. These matters involve risks and uncertainties, and the company’s actual results may differ significantly due to a variety of factors that are discussed in detail in the company’s SEC filings.

And with that, I’d like to turn the call over to Dr. Werner Cautreels, Chief Executive Officer of Traws Pharma. Please go ahead, Werner.

Werner Cautreels

Thank you, Tara, and good morning, everyone. I am Werner Cautreels, and I’m CEO of Traws Pharma. Welcome everyone to Traws’ investor event, and thank you for joining us today. Today’s event is an important event for Traws. We will discuss the unmet needs and the public health risk in bird flu and COVID, our two antiviral product candidates.

Our two main speakers today are Dr. Robert Redfield and Dr. David Pauza. Dr. Redfield is our Chief Medical Officer, and previously was Director of the CDC. Dr. Pauza is our Chief Science Officer and will be presenting the data of the compound. Today also, our Executive Chairman, Dr. Iain Dukes, will be part of today’s call, and some other members of the management team will be available also to take your questions and answer those questions.

We believe that our antiviral compounds have the potential to be best-in-class compounds, as you will hear today. Our lead program is tivoxavir marboxil in development for bird flu. We will also introduce ratutrelvir in development for COVID....

Read the full article on Seeking Alpha

For further details see: